Ambulatory high-dose methotrexate administration among pediatric osteosarcoma patients in an urban, underserved setting is feasible, safe, and cost-effective

Pediatric Blood and Cancer

Volumn 55, Issue 7, 2010, Pages 1296-1299

  Mahadeo, Kris M ^a   Santizo, Ruth ^a   Baker, Lindsay ^a   Curry, Joan O'Hanlon ^a   Gorlick, Richard ^a   Levy, Adam S ^a  

^a CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

Author keywords

Chemotherapy; Cost effective; Methotrexate; Osteosarcoma; Pediatric oncology; Underserved

Indexed keywords

BICARBONATE; METHOTREXATE;

ADULT; ALKALINIZATION; AMBULATORY CARE; ARTICLE; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG BLOOD LEVEL; DRUG COST; DRUG MEGADOSE; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; HOSPITAL COST; HUMAN; INFUSION PUMP; LEUKOPENIA; MALE; MEDICALLY UNDERSERVED; NEUTROPENIA; OSTEOSARCOMA; OUTPATIENT CARE; PATIENT MONITORING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; THROMBOCYTOPENIA; URBAN AREA; URINE PH;

ADOLESCENT; ADULT; AMBULATORY CARE; ANTIMETABOLITES, ANTINEOPLASTIC; BONE NEOPLASMS; CHILD; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; FEMALE; HOME INFUSION THERAPY; HOSPITAL CHARGES; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MEDICALLY UNDERSERVED AREA; METHOTREXATE; OSTEOSARCOMA; URBAN POPULATION; YOUNG ADULT;

EID: 78049264040     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22772     Document Type: Article

References (23)

1. Aquerreta I, Aldaz A, Giraldez J, et al. Pharmacodynamics of high-dose methotrexate in pediatric patients. Ann Pharmacother 2002; 36: 1344-1350.
2. Zelcer S, Kellick M, Wexler LH, et al. The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue. Pediatr Blood Cancer 2008; 50: 1176-1180.
3. Close P, Burkey E, Kazak A, et al. A prospective, controlled evaluation of home chemotherapy for children with cancer. Pediatrics 1995; 95: 896-900.
4. Adamson PC, Balis FM, Berg S, et al. In: Pizzo PA, Poplack DG, editors. General principles of chemotherapy: Principles and practices of pediatric oncology, 5th edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2006. pp. 318-322.
5. Treon SP, Chabner BA. Concepts in the use of high-dose methotrexate therapy. Clin Chem 1996; 42: 1322-1329.
6. Jaffe N, Gorlick R. High-dose methotrexate in osteosarcoma: Let the questions surcease-Time for final acceptance. J Clin Oncol 2008; 26: 4365-4366.
7. Mir O, Ropert S, Goldwasser F. Neoadjuvant chemotherapy with high-dose methotrexate in osteosarcoma. Lancet 2008; 9: 1198.
8. Rosen G, Marcove RC, Caparros B, et al. Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery. Cancer 1979; 43: 2163-2177.
9. Kim MS, Cho WH, Song WS, et al. Time dependency of prognostic factors in patients with stage II osteosarcomas. Clin Orthop Relat Res 2007; 463: 157-165.
10. Jaffe N, Link M, Traggis D, et al. The role of high-dose methotrexate in osteogenic sarcoma in sarcomas in soft tissue and bone in childhood. Natl Cancer Inst Monogr 1981; 56: 201-206.
11. Von Hoff DD, Penta IS, Helman U, et al. Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration. Cancer Treat Rep 1977; 61: 745-748.
12. Pitman SW, Frei EI II. Weekly methotrexate-calcium leucovorin rescue: Effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkins lymphoma. Cancer Treat Rep 1977; 61: 695-701.
13. Redlener I, Grant R, Krol DM. Beyond primary care: Ensuring access to subspecialists, special services, and health care systems for medically underserved children. Adv Pediatr 2005; 52: 9-22.
14. Kagawa-Singer M. Improving the validity and generalizability of studies with underserved U.S. populations expanding the research paradigm. Ann Epidemiol 2000; 10: S92-S103.
15. Hillier DF, Parry GJ, Shannon MW, et al. The effect of hospital bed occupancy on throughput in the pediatric emergency department. Ann Emerg Med 2009; 53: 767-776.
16. Liu SW, Thomas SH, Gordon JA, et al. A pilot study examining undesirable events among emergency department-boarded patients awaiting inpatient beds. Ann Emerg Med 2009; 54: 381-385.
17. Shea AM, Curtis LH, Hammill BG. Association between the Medicare Modernization Act of 2003 and patient wait times and travel distance for chemotherapy. J Am Med Assoc 2008; 300: 189-196.
18. Chesney DS, Brouhard BH, Cunningham RJ. Safety and cost effectiveness of pediatric percutaneous renal biopsy. Pediatr Nephrol 1996; 10: 493-495.
19. Sulkes DJ, Scott IU, Flynn HW, et al. Evaluating outpatient versus inpatient costs in endopthalmitis management. Retina 2002; 22: 747-751.
20. Pauly MV, Erder MH. Insurance incentives for ambulatory surgery. Health Serv Res 1993; 27: 813-839.
21. Vokes EE, Schilsky RL, Choi KE, et al. A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer. Cancer 1989; 63: 30-36.
22. Stevens B, Croxford R, McKeever P, et al. Hospital and home chemotherapy for children with leukemia: A randomized cross-over study. Pediatr Blood Cancer 2006; 47: 285-292.
23. Borras JM, Sanchez-Hernandez A, Navarro M, et al. Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: A randomised controlled trial. Br Med J 2001; 322: 826-829.